Maternal Docosahexaenoic Acid Supplementation and Bronchopulmonary Dysplasia in Infants—Reply

Abstract

In Reply Dr van den Akker and colleagues propose a possible explanation linking potential deficits in proresolving lipid mediator synthesis to why DHA failed to improve bronchopulmonary dysplasia in both the N3RO¹ and MOBYDIck trials.² As they mentioned, proresolving lipid mediators D and E resolvin series derived from DHA and eicosapentaenoic acid, respectively, have potent roles in the active regulation of inflammatory processes. Arachidonic acid–derived lipoxins appear particularly important for initiating the resolution of the inflammatory cascade.